KR20240019241A - Setd2 억제제를 사용한 조합 요법 - Google Patents

Setd2 억제제를 사용한 조합 요법 Download PDF

Info

Publication number
KR20240019241A
KR20240019241A KR1020247000394A KR20247000394A KR20240019241A KR 20240019241 A KR20240019241 A KR 20240019241A KR 1020247000394 A KR1020247000394 A KR 1020247000394A KR 20247000394 A KR20247000394 A KR 20247000394A KR 20240019241 A KR20240019241 A KR 20240019241A
Authority
KR
South Korea
Prior art keywords
alkyl
group
compound
cycloalkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000394A
Other languages
English (en)
Korean (ko)
Inventor
마리아 알레한드라 라이몬디
제니퍼 앤 토트만
비니 모트와니
캐서린 루이스 코스모풀로스
도로시 브라치
다니엘 티. 드란스필드
Original Assignee
에피자임, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피자임, 인코포레이티드 filed Critical 에피자임, 인코포레이티드
Publication of KR20240019241A publication Critical patent/KR20240019241A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247000394A 2021-06-09 2022-06-08 Setd2 억제제를 사용한 조합 요법 Pending KR20240019241A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208882P 2021-06-09 2021-06-09
US63/208,882 2021-06-09
PCT/US2022/032718 WO2022261243A1 (en) 2021-06-09 2022-06-08 Combination therapies with setd2 inhibitors

Publications (1)

Publication Number Publication Date
KR20240019241A true KR20240019241A (ko) 2024-02-14

Family

ID=84425539

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000394A Pending KR20240019241A (ko) 2021-06-09 2022-06-08 Setd2 억제제를 사용한 조합 요법

Country Status (10)

Country Link
US (1) US20240299352A1 (enExample)
EP (1) EP4351552A4 (enExample)
JP (1) JP2024522184A (enExample)
KR (1) KR20240019241A (enExample)
CN (1) CN117794543A (enExample)
AU (1) AU2022288073A1 (enExample)
CA (1) CA3221071A1 (enExample)
IL (1) IL308868A (enExample)
MX (1) MX2023014663A (enExample)
WO (1) WO2022261243A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272379B2 (en) 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法
WO2025034951A1 (en) * 2023-08-09 2025-02-13 Enanta Pharmaceuticals, Inc. Pharmaceutical compounds and compositions as c-kit kinase inhibitors
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
WO2015150097A1 (en) * 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
IL272379B2 (en) * 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) * 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
WO2020112872A1 (en) * 2018-11-30 2020-06-04 Epizyme, Inc. Methods of treating whsc1-overexpressing cancers by inhibiting setd2
CN121695288A (zh) * 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Also Published As

Publication number Publication date
EP4351552A4 (en) 2025-06-18
US20240299352A1 (en) 2024-09-12
CN117794543A (zh) 2024-03-29
JP2024522184A (ja) 2024-06-11
MX2023014663A (es) 2024-05-08
CA3221071A1 (en) 2022-12-15
AU2022288073A1 (en) 2023-12-07
WO2022261243A1 (en) 2022-12-15
IL308868A (en) 2024-01-01
EP4351552A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
TWI828677B (zh) 甲基修飾酵素之調節劑、其組成物及用途
CA2926328C (en) Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
JP7627209B2 (ja) 置換インドール及びその使用方法
CA2699707C (en) Inhibitors of the interaction between mdm2 and p53
CN115380033B (zh) Setd2抑制剂和相关方法和用途，包括组合疗法
KR101749192B1 (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
WO2023099592A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
AU2022288073A1 (en) Combination therapies with setd2 inhibitors
CA2843499A1 (en) Indazole compounds, compositions and methods of use
JP2020502246A (ja) ２−ベンゾピラジニル−ｎ−ヘテロアリール−２−フェニル−アセトアミド化合物
EP3347351B1 (en) Salts of a pim kinase inhibitor
TW202339736A (zh) 化合物及使用方法
WO2021074251A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer
EA038233B1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
TW201902892A (zh) 化合物
JP6889661B2 (ja) ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用
HK40084091A (en) Setd2 inhibitors and related methods and uses, including combination therapies
HK40026650B (en) Aminopyrimidine derivatives, preparation method therefor and use thereof
HK40026650A (en) Aminopyrimidine derivatives, preparation method therefor and use thereof
HK1256806B (en) Salts of a pim kinase inhibitor
CA2981530A1 (en) Substituted quinazoline compounds and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250605

Comment text: Request for Examination of Application